Europe's Mastocytosis Network Marks 20 Years of Rare Disease Progress
A European research collaboration has documented two decades of advances in understanding and treating mastocytosis, a rare immune disorder that affects thousands. The milestone report suggests improved diagnostic and management approaches that could reshape how pharmaceutical companies and healthcare systems address uncommon allergic and hematologic diseases.
Originaltitel: European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
<p>In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders.</p>